- Home
- VERI vs PLX Comparison
VERI vs PLX Comparison
Compare VERI & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VERI | PLX |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.0M | 230.0M |
| IPO Year | 2017 | 1996 |
Fundamental Metrics
Financial Performance| Metric | VERI | PLX |
|---|---|---|
| Price | $2.86 | $2.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $10.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $92,637,000.00 | $53,399,000.00 |
| Revenue This Year | $20.56 | $9.67 |
| Revenue Next Year | $19.11 | $23.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.29 | $1.34 |
| 52 Week High | $9.42 | $3.19 |
Technical Indicators
Market Signals| Indicator | VERI | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 38.94 | 50.71 |
| Support Level | $2.61 | $2.59 |
| Resistance Level | $3.15 | $3.03 |
| Average True Range (ATR) | 0.19 | 0.13 |
| MACD | 0.05 | -0.05 |
| Stochastic Oscillator | 27.03 | 36.21 |
Price Performance
Historical ComparisonAbout VERI Veritone Inc.
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has a presence in the United States, the United Kingdom, France, Australia, Israel, and India.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.